Icariin |
Human lung adenocarcinoma cells (A459) |
In vitro and In vivo
|
Activation of ERS signaling, increased expression of ERS-related molecules (p-ERK, ATF6, GRP78, p-eIF2α, and CHOP, downregulation of Bcl2 expression and upregulation of PUMA |
Di et al., 2015
|
|
Human esophageal cancer cells (EC109 and TE1) |
In vitro and In vivo
|
Activation of ERS signaling, increased expression of ERS-related molecules (p-ERK, ATF4, GRP78, p-eIF2α, and CHOP, downregulation of Bcl2 expression and upregulation of PUMA |
Fan et al., 2016
|
|
Human hepatoma cells (SMMC-7721, Bel-7402, and HepG2) |
In vitro and In vivo
|
Activation of ROS/JNK-dependent mitochondrial pathway that involved the generation of ROS and JNK activation, resulted in enhanced Bax-to-Bcl-2 ratio, loss of mitochondrial membrane potential, cytochrome c release, and caspase cascade |
Li et al., 2010
|
|
Mouse tumor Leydig cells (MLTC-1) |
In vitro |
Activation of caspase-9, -3, enhanced Bax/Bcl-2 ratio, and release of cytochrome c, as well as down-regulation of the expression of piwil4 |
Wang et al., 2011a
|
Icaritin |
Hepatocellular Carcinoma (HepG2) |
In vitro |
Enhanced Bax/Bcl-2 ratio, activation of caspase-3, activation of JNK1 signaling |
He et al., 2010
|
|
Leukemia cells (Primary acute myeloid leukemia cells, NB4, HL60, and U937) |
In vitro |
Activation of caspase-9, -3, -7, cleavage of PARP, downregulation of c-myc, inhibition of MAPK/ERK, and PI3K/AKT signals. |
Li et al., 2013a
|
|
Human Burkitt lymphoma cells (Raji and P3HR-1) |
In vitro |
Activation of caspase-8, -9, cleavage of PARP, downregulation of c-myc and enhanced Bax/Bcl-2 ratio |
Li et al., 2014b
|
|
Human liver cells (L02) and Human hepatocarcinoma cells (SMMC-7721) |
In vitro |
Activation of caspase-3, -8, enhanced Bax/Bcl-2 ratio, increased expression levels of Fas |
Sun et al., 2015b
|
|
Human endometrial cancer cells (Hec1A) |
In vitro |
Activation of caspase-3 and caspase-9, cleavage of PARP, release of cytochrome c, enhanced Bax/Bcl-2 ratio, and sustained activation ERK1/2 signaling |
Tong et al., 2011
|
|
Extranodal NK/T-cell lymphoma cells (SNK-10 and SNT-8) |
In vitro |
Activation of caspase-3 and caspase-9, enhanced Bax/Bcl-2 ratio, downregulation of p-Bad, inhibition of Jak/Stat3, and PI3K/Akt signaling pathway mediated by reduced expression of LMP1 |
Wu et al., 2015b
|
|
Leukemia cells (Primary chronic myeloid leukemia cells and K562) |
In vitro and In vivo
|
Activation of caspase-3, -9, release of cytochrome c, enhanced Bax/Bcl-2 ratio, downregulated expression of Apaf-1, inhibition of MAPK/ERK/JNK signals and down-regulated kinase activity of Jak-2/STAT3/Akt signal network |
Zhu et al., 2011
|
Icariside II |
Human hepatoblastoma cells (HepG2), Mouse liver carcinoma cells (H22) |
In vitro and In vivo
|
Mitochondrion membrane and lysomal membrane permeabilization, activation of caspase-3, -7, -8, -9, cleavage of PARP, enhanced Bax/Bcl-2 ratio. |
Geng et al., 2015
|
|
Human breast cancer cells (MCF-7) |
In vitro |
Activation of caspase-8, -9, decreased mitochondrial potential, release of cytochrome C and AIF, increased expression of Fas and FADD as well as increased expression of Bax and BimL |
Huang et al., 2012
|
|
Human acute myeloid leukemia cells (U937) |
In vitro |
Activation of caspase-3, cleavage of PARP, and decreased bcl-xL and survivin, inactivation of STAT3-related signaling pathway. |
Kang et al., 2012
|
|
Multiple myeloma cells (U266) |
In vitro |
Down-regulation of expression of Bcl-2, Bcl-xL, survivin, Cyclin D1, COX-2, and VEGF, enhanced PARP cleavage and caspase-3 activation, inhibition of STAT3 activation and enhanced expression of SHP-1 and PTEN through inhibiting JAK2 and c-Src |
Kim et al., 2011
|
|
Human prostate cancer cells (PC-3) |
In vitro |
Activation of caspase-8, -9, -3, cleavage of PARP, decreased mitochondrial potential, COX-2, iNOS, and VEGF expression, release of cytochrome C, inhibition of COX-2/PGE2 pathway |
Lee et al., 2009
|
|
Human non-small cell lung cancer cells (A549) |
In vitro |
Activation of caspase-3, -9, cleavage of PARP, release of cytochrome c, enhanced Bax/Bcl-2 ratio, Activation of ROS/MAPK pathway that involved activation of ROS downstream effectors, JNK and p38MAPK |
Song et al., 2012
|
|
Human eosophageal squamous carcinoma (Eca109) |
In vitro and In vivo
|
Downregulation of survivin and Cyclin D1, inhibition of β-catenin-dependent signaling. |
Wang et al., 2011b
|
|
Human epidermoid carcinoma cells (A431) |
In vitro |
Activation of caspase-9, cleavage of PARP, inhibition of JAK/STAT3 and MAPK-ERK pathways, activation of PI3K/AKT pathway, inhibition of EGF-induced activation of EGFR pathway. |
Wu et al., 2013b
|
|
Human melanoma cells (A375 and SK-MEL-5) and Mouse melanoma cells (B16) |
In vitro and In vivo
|
Activation of caspase-3, decreased expression of survivin, inhibition of JAK/STAT3 and MAPK pathways as well as activation of PI3K/AKT pathway |
Wu et al., 2013a
|